Endometriosis is a chronic disease that occurs when tissue similar to that in the lining of the uterus grows outside the uterus. It affects 190 million women and girls of reproductive age globally. Symptoms include severe pelvic pain, pain during sexual intercourse, bloating, nausea, fatigue, painful bowel movements and urination, and sometimes infertility. Treatment aims to help control symptoms, as there is currently no cure.
Endometriosis affects 10% of menstruating women and presents complex challenges in pain assessment and management. Traditional methods of assessing pain rely on subjective self-reporting, leading to variations in evaluation and potential biases. Chugai Pharmaceutical utilized the unique capabilities of Empatica’s technology to overcome this challenge. In a groundbreaking study lasting 3 months with 90 endometriosis patients, Empatica’s wearable devices were used to capture data to assess the correlation of pain quantification against traditional methods. The goal is to develop digital biomarkers to objectively measure pain, using data collected by EmbracePlus and correlating physiological responses like pulse rate and electrodermal activity with pain, for remote endometriosis patients monitoring.
Chugai Pharma is dedicated to creating and delivering innovative products and services for the medical community and improving human health across the world.